Abstracts Archive - Page 27 of 2425 - ACR Meeting Abstracts

Abstract Number: 0168 • ACR Convergence 2024
Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database
Tatsuya Atsumi¹, Hironari Hanaoka², Nobuo Nishijima³, Kohji Murakami⁴, Mariko Nio³, Tsutomu Urakawa³, Takaaki Fujimura³ and Hiroki Hayashi⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁴Nippon Shinyaku Co., Ltd., Tokyo, Japan, ⁵Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Background/Purpose: Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus (SLE), affecting morbidity and mortality in SLE. LN is…
Abstract Number: 0087 • ACR Convergence 2024
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Ethan Jung¹, Marie semana¹, Ivan Cheng¹, Helena Silva¹, Sandro Vivona¹, Somya Singh¹, Michele Bauer¹, Mohammed Ali¹, Henry Rosas¹, Woei Chang¹, Deepti Rokkam¹, Patrick Lupardus¹, Martin Oft¹ and Paul-Joseph Aspuria², ¹Synthekine, Menlo Park, ²Sythekine, Menlo Park, CA
Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
Abstract Number: 0092 • ACR Convergence 2024
A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis
Hulya Bukulmez¹, Adrienne Dennis², kristine Highland³ and Steven N. Emancipator⁴, ¹MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, ²MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH, ⁴Case Western Reserve University, Cleveland, OH
Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…
Abstract Number: 0001 • ACR Convergence 2024
Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus
Diana Alzamareh¹, Nida Pellett², Daria Krenitsky², Wesley Durrett¹, Javier Rangel-Moreno¹, Jennifer Anolik² and Jennifer Barnas¹, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of pathogenic anti-nuclear antibodies (ANA) by plasma cells (PC). Importantly, long-lived plasma…
Abstract Number: 0142 • ACR Convergence 2024
The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis
Nidaa Rasheed¹, kHALED ABDULLAH² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Gout is characterized by chronic inflammatory arthritis caused by the deposition of monosodium urate crystals and leads to increased risk of complications, such as…
Abstract Number: 0036 • ACR Convergence 2024
Deep Topic Modeling Deconvolves Cell States in Spatial Transcriptomic Profiles of Rheumatoid Arthritis Synovial Tissue
Preethi Periyakoil¹, Melanie Smith², Meghana Kshirsagar³, Daniel Ramirez⁴, Edward Dicarlo⁵, Susan Goodman⁶, Laura Donlin² and Christina Leslie⁷, ¹Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Microsoft AI for Good, Seattle, ⁴Hospital for Special Surgery, Cartago, Costa Rica, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Recent single-cell RNA sequencing (scRNA-seq) studies of the rheumatoid arthritis (RA) synovium have highlighted the heterogeneity of cell states present during active disease. It…
Abstract Number: 0007 • ACR Convergence 2024
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Ryota Sato¹, Mitsuhiro Akiyama², Koichi Oshita³, Yuko Kawano³, Yuki Imura³, Piruzyan Mariam⁴, Manami Kikuchi³, Mikako Murase³, Sachiko Mochiduki³, Naohiro Hashimoto³, Masayuki Watanabe³, Keiko Yoshimoto⁵, Tsutomu Takeuchi⁶, Kenji Chiba⁷ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Brighton, MA, ²Keio University School of Medicine, Palo Alto, CA, ³Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
Abstract Number: 0013 • ACR Convergence 2024
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Jordan Anderson², Nathan Rollins², Tobias Green², Agustin Plasencia², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting immune cell responses that cause tissue damage in autoantibody-mediated diseases such as idiopathic inflammatory myopathies, lupus…
Abstract Number: 0099 • ACR Convergence 2024
Modulating Pentose Phosphate Pathway Metabolism to Temper Neutrophil Hyperactivity in Antiphospholipid Syndrome
Kaitlyn Sabb¹, Ajay Tambralli¹, Megan Radyk¹, Emily Becker¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Cyrus Sarosh², Jacqueline Madison¹, Yu Zuo¹, Costas Lyssiotis¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play important roles in antiphospholipid syndrome (APS) pathogenesis. To kill microbes and propel…
Abstract Number: 0108 • ACR Convergence 2024
Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)
Fernanda Oliveira de Andrade Lopes¹, Andreia Coimbra Sousa², Massimo Radin³, Gustavo Balbi⁴, Irene Cecchi³, Savino Sciascia⁵, Flavio Victor Signorelli⁶ and Danieli Andrade², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²University of São Paulo, São Paulo, SP, Brazil, ³University of Turin, Turin, Italy, ⁴Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil, ⁵University of Turin, Torino, Turin, Italy, ⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…
Abstract Number: 0095 • ACR Convergence 2024
Expansion of Brain T Cell Subsets Outside of the Choroid Plexus in Murine Models of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Minjung Kim¹, Cecilia Stumpf², Hadijat Makinde¹, Mohammad Khan¹, Vanessa Rodriguez², Tyler Therron², Jeremy Tilstra³, Deborah Winter⁴ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³University of Pittsburgh, Pittsburgh, PA, ⁴Northwestern University, Skokie, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (psychosis, anxiety disorder, cognitive dysfunction) may lead to the devastating impact of this disease on patients’ health-related quality-of-life, representing…
Abstract Number: 0024 • ACR Convergence 2024
Trans-Signaling by Soluble CD14 Sensitizes Chondrocytes to Lipopolysaccharide Stimuli, Increasing Chondrocyte Inflammatory Responses
Anna E. Rapp, Baofeng Hu and Carla Scanzello, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The understanding of osteoarthritis (OA) has evolved significantly over the past decade. Recently attention is being drawn to the role of pattern-recognition receptor (PRR)…
Abstract Number: 0029 • ACR Convergence 2024
Effect of Metformin on the Incidence of Total Knee Replacement: A Systematic Review and Meta-Analysis
Syed Hasan¹, Aali Furqan², Afia Salman³, hira Khan⁴, Sarah Aslam⁵, Alishba Rizvi⁴, Hafsah Alim Ur Rahman³, Muhammad Ahmed Ali Fahim³, Madiha Salman³, Eman Ali³, Yumna Furqan⁶, Shanta bai⁷, Farah Yasmin⁸ and Muhammad Sohaib Asghar⁹, ¹Dow University of Health Sciences, Karachi, PK., Karachi, Sindh, Pakistan, ²University of North Texas Health Science Center (UNT HSC), Texas, TX, ³Dow University of Health Sciences, Karachi, Pakistan, ⁴dow medical college, Karachi, Pakistan, ⁵Dow International Medical College, Karachi, Pakistan, ⁶Texas A&M School of Medicine, Dallas, TX, ⁷Liaquat National Hospital and Medical College, Karachi, Pakistan, ⁸Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, ⁹AdventHealth, Sebring, FL
Background/Purpose: Osteoarthritis (OA) is among the most common debilitating conditions, causing disability and pain in older adults. For end-stage OA, total knee replacement (TKR) is…
Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Ashley Mahne¹, Ryan Rodriguez², Jessica Wang¹, Daniel Anaya¹, Joseph K. Cheng¹, Brandon Kwong¹, Jesus Banuelos³, Peter Starokadomskyy³, Soo Park³, Candice Gibson⁴, Shouvonik Sengupta¹, Simone Sandoval¹, Jazmin Bravo³, Jeanne Flandez¹, Shairaz Shah¹, Amanda Goodsell¹, Nicole Khoshnoodi¹, Jennifer Zeng¹, Santiago Foos-Russ¹, Mario Lorente¹, Jennifer Adrian¹, Timothy Klasson¹, Yong Zhang⁵, Jessica Seitzer⁶, Birgit Schultes⁵ and Tom Van Blarcom³, ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emerville, CA, ³Kyverna Therapeutics, Inc., Emeryville, ⁴Kyverna Therapeutics, Inc., Emerybille, ⁵Intellia Therapeutics, Inc., Cambridge, MA, ⁶Intellia Therapeutics, Inc., Cambridge
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
Abstract Number: 0063 • ACR Convergence 2024
Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils
Rayan Najjar¹, Noga Rogel² and Tomas Mustelin³, ¹University of Washington, Seattle, ²University of Washinton, Seattle, ³University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by a variable response to therapies, reflecting its complex and incompletely understood pathogenesis. Emerging research suggests…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].